Bahrain's National Health Regulatory Authority said on Sunday it had approved the registration of a coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm), according to Reuters. The statement did not specify which vaccine among the two being developed by Sinopharm, but cited data from Phase III clinical trials that showed an 86% efficacy rate and said Bahrain had participated in those trials. The data cited was the same as what was announced earlier this month by the United Arab Emirates from interim analysis of late-stage clinical trials for an inactivated vaccine developed by Beijing Institute of Biological Product, a unit of Sinopharms' China National Biotec Group (CNBG). Bahrain, which earlier this month granted emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine, had said on Dec. 10 that it would provide COVID-19 vaccine for free for all citizens and residents. In fellow Gulf Arab state Kuwait, the Ministry of Health on Sunday granted emergency use authorization for the Pfizer/BioNTech vaccine, Kuwait news agency (KUNA) said.
